ClinicalTrials.gg
TerminatedNCT01755858EVOLVEUpdated Aug 11, 2020Results posted

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

A Phase 1/2 interventional study of Bendavia and Placebo in Renal Artery Obstruction, Hypertension, Renovascular and Ischemia Reperfusion Injury, sponsored by Stealth BioTherapeutics Inc.. Terminated at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.

Enrollment
13th of 14
16 · median 64
Started
2012
with 2 others
Phase 1/2
Only one
of the 16
Registered
13th of 16
by date

Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2012, is the only one in phase 1/2, and was the 13th registered.

Renal Artery Obstruction

59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.

Browse Renal Artery Obstruction studies →

Open to participants now

None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →

Who these studies take

Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Renal Artery Obstruction with a site in United States as a file.
02

Study summary

This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal Artery Stenosis (ARAS), who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).

Read the detailed description

This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV elamipretide for reduction of reperfusion injury in subjects with ARAS, who are undergoing percutaneous transluminal angioplasty of the renal artery (PTRA).

The randomization (1:1 active:placebo) was stratified by a diagnosis of diabetes mellitus. Participants received either 0.05 mg/kg/h elamipretide or matching placebo, administered as an IV infusion at 60 mL/h infused 30 minutes before and continued 3 hours after PTRA of the renal artery. After completion of the PTRA and stenting, subjects were to receive standard treatment.

03

Conditions studied

  • Renal Artery Obstruction
  • Hypertension, Renovascular
  • Ischemia Reperfusion Injury

Keywords

  • elamipretide
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥40 and ≤80 years old.
  • Patients with hypertension (systolic blood pressure [BP] >155 mm Hg) and/or requiring 2 or more antihypertensive medications: no restrictions will be placed on antihypertensive agents, although loop diuretics will be temporarily changed to diluting site agents (eg, hydrochlorothiazide, indapamide, metolazone) prior to each blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) study performed during the trial, unless, in the judgment of the Investigator, the change represents a hazard to the patient. ARAS patients will be identified based upon radiologic and clinical criteria suggestive of renovascular hypertension and/or hemodynamically significant renovascular disease >60% lumen occlusion (determined by quantitative computed tomography angiography or Doppler ultrasound velocity >200 cm/sec).
  • Have an estimated of ≥15 ml/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula.
  • Have no to angiography such as severe contrast allergy.
  • Have no contraindications to non-contrast magnetic resonance evaluations such as a pacemaker or magnetically active metal fragments.
  • Able to comply with protocol.
  • Women of childbearing age must:
  • Have a negative pregnancy serum human chorionic gonadotropin test prior to receiving study drug.
  • Agree to use two forms of for 3 months following receipt of the study drug.
  • Men who are sexually active and able to father a child, must agree to use one of the birth control methods listed below for the entire study and for at least 2 months after receiving the study drug:
  • Barrier methods (such as a condom or diaphragm) used with a spermicide.
  • Hormonal methods used by his partner, such as birth control pills, patches, injections, vaginal ring, or implants.
  • Intrauterine device (IUD) used by his partner.
  • Abstinence (no sex).
  • Competent and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Advanced chronic kidney disease defined as either Stage 5 or end-stage renal disease requiring dialysis.
  • Have other abnormalities or laboratory results that would, in the opinion of the investigators, compromise the safety of the patient including evidence of diabetic ketoacidosis, paraproteinemia, or triglycerides above 600 mg/dL.
  • Clinically significant medical conditions within the six months before administration of Bendavia (e.g., cancer, stroke, myocardial infarction, active angina, congestive heart failure) that would, in the opinion of the investigators, compromise the safety of the patient.
  • Have received an drug within thirty (30) days of baseline.
  • Have a serum sodium \<135 mmol/L on the day of, and prior to, the PTRA.
  • Are pregnant or breast feeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Bendavia

    Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.

    Drug: Bendavia

  • Placebo comparator
    Placebo

    Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.

    Drug: Placebo

Interventions

  • Also known as: MTP-131, Elamipretide

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.

    Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..

    Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA

Secondary outcomes

  1. Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.

    Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.

    Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA

  2. Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA

    Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.

    Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA

  3. Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA

    Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys

    Time frame: Baseline (pre-PTRA) and 8 weeks post-PTRA

  4. Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.

    Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.

    Time frame: Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA

  5. Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA

    Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.

    Time frame: Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA

  6. Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA

    Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia

    Time frame: 27H post PTRA and 8 weeks Post PTRA

  7. Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA

    Time frame: Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA

  8. Mean Change in Diastolic Blood Pressure

    Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.

    Time frame: Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA

07

Results

Posted Aug 11, 2020

Participant flow

Participant flow — Overall Study
MilestoneBendaviaPlacebo
Started79
Completed68
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryChange in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.

Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..

Time frame:
Baseline (pre-PTRA) and 8 weeks post-PTRA
Reported as:
Mean · mL/min
Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.
mL/minBendaviaPlacebo
Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.6.3 ± 12.1412.0 ± 23.84
SecondaryChange in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.

Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.

Time frame:
Baseline (pre-PTRA) and 8 weeks post-PTRA
Reported as:
Mean · mL/min
Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
mL/minBendaviaPlacebo
Right Single Kidney0.238 ± 0.25570.010 ± 0.0552
Left Single Kidney0.012 ± 0.14870.120 ± 0.1600
SecondaryChange in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA

Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.

Time frame:
Baseline (pre-PTRA) and 8 weeks post-PTRA
Reported as:
Mean · mL/min
Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
mL/minBendaviaPlacebo
Right Cortical1.266 ± 0.9341-0.816 ± 0.6614
Right Medullary0.242 ± 0.4143-0.082 ± 0.2541
Left Cortical0.614 ± 1.23900.220 ± 0.9112
Left Medullary0.150 ± 0.37880.156 ± 0.5184
SecondaryChange in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA

Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys

Time frame:
Baseline (pre-PTRA) and 8 weeks post-PTRA
Reported as:
Mean · mL/min
Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA
mL/minBendaviaPlacebo
Right Cortical85.056 ± 63.2943-28.406 ± 54.8919
Right Medullary6.658 ± 20.3007-10.204 ± 21.2044
Right Total91.712 ± 82.4794-38.608 ± 43.4011
Left Cortical23.928 ± 64.489135.090 ± 59.9470
Left Medullary3.610 ± 14.49515.930 ± 19.0256
Left Total27.538 ± 78.072841.018 ± 75.6824
SecondaryChange in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.

Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.

Time frame:
Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA
Reported as:
Mean · mL
Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.
mLBendaviaPlacebo
Right Total Kidney Volume1.270 ± 12.82184.708 ± 13.7198
Left Total Kidney Volume5.090 ± 17.695110.220 ± 8.9447
Right Cortical4.372 ± 10.54389.840 ± 13.1156
Right Medullary-3.162 ± 4.7616-5.132 ± 7.0670
Left Cortical4.534 ± 15.045910.100 ± 10.8462
Left Medullary0.558 ± 3.10160.120 ± 8.6277
SecondaryMean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA

Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.

Time frame:
Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA
Reported as:
Mean · s^-1
Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA
s^-1BendaviaPlacebo
AxialRightPrefurosemideFractHyp%>20 27H Post PTRA13.440 ± 34.682516.708 ± 19.4980
AxialRightPrefurosemideFractHyp%>20; 8Wk Post PTRA-3.380 ± 8.5013-10.892 ± 15.370
AxialRightPrefurosemideFractHyp%>30 27H PostPTRA5.206 ± 9.487511.600 ± 17.8192
AxialRightPrefurosemideFractHyp%>30 8Wk PostPTRA-2.120 ± 2.7426-1.840 ± 2.8693
AxialRightPostfurosemideFracHyp%>20 27HPostPTRA24.280 ± 27.620613.854 ± 26.2292
AxialRightPostfurosemideFracHyp%>20 8WkPostPTRA28.625 ± 8.9537-7.560 ± 13.5471
AxialRightPostfurosemideFracHyp %30 27H Post PTRA6.080 ± 7.690413.490 ± 21.1322
AxialRightPostfurosemideFracHyp%>30 8WkPost PTRA-0.400 ± 2.9473-1.370 ± 3.4412
AxialLeftPrefurosemide Frac Hyp%>20 27H Post PTRA1.320 ± 21.769412.767 ± 26.0745
AxialLeftPrefurosemide Frac Hyp%>20 8Wk Post PTRA-0.420 ± 17.3066-8.160 ± 16.4477
AxialLeft Prefurosemide Frac Hyp %>30 27H PostPTRA-3.128 ± 3.015416.938 ± 25.4089
AxialLeft PrefurosemideFrac Hyp %>30 8Wk PostPTRA-0.602 ± 7.1510-6.360 ± 11.3054
AxialLeft Post-FurosemideFrac Hyp%>20 27HPostPTRA0.148 ± 21.018414.083 ± 34.6825
AxialLeft Post-FurosemideFrac Hyp%>20 8WkPostPTRA-0.012 ± 17.3829-14.220 ± 13.303
AxialLeft Post-FurosemideFrac Hyp%>30 27HPostPTRA-1.874 ± 2.511118.757 ± 27.1441
AxialLeft Post-FurosemideFrac Hyp%>30 8WkPostPTRA1.858 ± 7.0087-5.704 ± 8.3550
SecondaryMean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA

Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia

Time frame:
27H post PTRA and 8 weeks Post PTRA
Reported as:
Mean · s^-1
Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA
s^-1BendaviaPlacebo
CoronalRtFractHypoxia% >20Prefuros.27HPost-PTRA20.314 ± 33.35259.083 ± 17.3368
CoronalRtFractHypoxia% >20Prefuros.8WkPost-PTRA4.140 ± 16.4690-2.220 ± 7.5549
CoronalRtFractHypoxia% >30Prefuros.27HPost-PTRA10.800 ± 9.67349.250 ± 30.6001
CoronalRtFractHypoxia% >30Prefuros8WkPost-PTRA3.300 ± 10.1403-2.852 ± 11.1986
CoronalRtFractHypoxia% >20Postfuros27HPost-PTRA29.800 ± 33.53283.840 ± 22.4825
CoronalRtFractHypoxia% >20Postfuros8WKPost-PTRA5.233 ± 7.5142-5.220 ± 4.6018
CoronalRtFractHypoxia% >30Postfuros27HPost-PTRA12.875 ± 13.266611.458 ± 32.8826
CoronalRtFractHypoxia% >30Postfuros8WkPost-PTRA2.233 ± 3.5119-8.158 ± 16.5393
CoronalLeftFractHypoxia% >20Prefuros.27HPost-PTRA5.000 ± 23.76746.033 ± 31.1820
CoronalLeftFractHypoxia% >20Prefuros.8WkPost-PTRA-3.125 ± 10.2970-0.525 ± 12.5077
CoronalLeftFractHypoxia% >30Prefuros.27HPost-PTRA-2.000 ± 8.927222.615 ± 35.6971
CoronalLeftFractHypoxia% >30Prefuros.8WkPost-PTRA-2.275 ± 4.4650-1.525 ± 12.3605
CoronalLeftFractHypoxia% >20Postfuros.27HPost-PTRA6.240 ± 24.56716.783 ± 29.1337
CoronalLeftFractHypoxia% >20Postfuros.8WkPost-PTRA3.375 ± 9.2525-0.700 ± 14.7384
CoronalLeftFractHypoxia% >30Postfuros.27HPost-PTRA0.080 ± 7.314520.345 ± 31.5024
CoronalLeftFractHypoxia% >30Postfuros.8WkPost-PTRA-0.250 ± 2.0873-4.225 ± 12.7899
SecondaryMean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA
Time frame:
Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA
Reported as:
Mean · mmHg
Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA
mmHgBendaviaPlacebo
27 Hours Post-PTRA-2.9 ± 14.78-3.8 ± 15.69
8 weeks Post PTRA13.2 ± 19.88-0.8 ± 30.83
SecondaryMean Change in Diastolic Blood Pressure

Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.

Time frame:
Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA
Reported as:
Mean · mmHg
Mean Change in Diastolic Blood Pressure
mmHgBendaviaPlacebo
27 Hours Post-PTRA3.6 ± 7.76-2.0 ± 9.88
8 Weeks Post PTRA0.0 ± 9.700.1 ± 9.80

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bendavia0/7 (0%)1/7 (14.3%)2/7 (28.6%)
Placebo0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventBendaviaPlacebo
Vascular PseudoaneurysmInjury, poisoning and procedural complications1/70/9
Cardiac Failure AcuteCardiac disorders0/71/9
Most frequent other events
Showing 10 of 21
Most frequent other events
EventBendaviaPlacebo
ConstipationGastrointestinal disorders0/72/9
Respiratory DistressRespiratory, thoracic and mediastinal disorders0/72/9
HypertensionVascular disorders1/71/9
HypotensionVascular disorders1/71/9
Blood sodium decreasedInvestigations1/71/9
ContusionInjury, poisoning and procedural complications1/70/9
DizzinessNervous system disorders1/70/9
Oedema peripheralGeneral disorders1/70/9
Labile Blood PressureVascular disorders0/71/9
Blood magnesium decreasedInvestigations0/71/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)BendaviaPlaceboTotal
Mean66.1 ± 6.4172.6 ± 7.7869.8 ± 7.72
Sex: Female, Male
Sex: Female, Male(Participants)BendaviaPlaceboTotal
Female437
Male369
Diabetes Mellitus Status
Diabetes Mellitus Status(Participants)BendaviaPlaceboTotal
Positive033
Negative7613
08

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Saad A, Herrmann SMS, Eirin A, Ferguson CM, Glockner JF, Bjarnason H, McKusick MA, Misra S, Lerman LO, Textor SC. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017 Sep;10(9):e005487. doi: 10.1161/CIRCINTERVENTIONS.117.005487. PubMed 28916603 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Dec 24, 2012
Start
Dec 2012
Primary completionActual
Dec 2015
CompletionActual
May 2016
Results first posted
Aug 11, 2020
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01755858
Responsible party
Sponsor
First posted
Dec 24, 2012
Start date
Dec 2012
Primary completion
Dec 2015
Completion
May 2016
Results posted
Aug 11, 2020
Last update
Aug 11, 2020

Study contacts

Stephen C Textor, MD
principal investigator · Mayo Clinic
Richard Straube, MD
study director · Stealth BioTherapeutics Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion